These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33461831)

  • 21. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. National Stop Transmission of Polio Program support for polio supplemental immunization activities in Nigeria 2012-2016: deployment of management support team.
    Edukugho AA; Waziri NE; Bolu O; Gidado SO; Okeke LA; Uba BV; Idris JM; Michael CA; Adegoke JO; Bammeke P; Adamu US; Nguku PM; Biya O; Ohuanbunwo CJ; Vertefeuille J; Damisa E; Wiesen E
    Pan Afr Med J; 2021; 40(Suppl 1):14. PubMed ID: 36157558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Who gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey.
    Danovaro-Holliday MC; Rhoda DA; Lacoul M; Prier ML; Gautam JS; Pokhrel TN; Dixit SM; Rajbhandari RM; Bose AS
    BMC Public Health; 2022 Feb; 22(1):221. PubMed ID: 35114969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distributing insecticide-treated bednets during measles vaccination: a low-cost means of achieving high and equitable coverage.
    Grabowsky M; Nobiya T; Ahun M; Donna R; Lengor M; Zimmerman D; Ladd H; Hoekstra E; Bello A; Baffoe-Wilmot A; Amofah G
    Bull World Health Organ; 2005 Mar; 83(3):195-201. PubMed ID: 15798843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018.
    Jean Baptiste AE; Masresha B; Wagai J; Luce R; Oteri J; Dieng B; Bawa S; Ikeonu OC; Chukwuji M; Braka F; Sanders EAM; Hahné S; Hak E
    Vaccine; 2021 Nov; 39 Suppl 3():C89-C95. PubMed ID: 33875267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential for improving routine immunisation waste management using measles vaccination campaign 2017 in Kebbi State, Nigeria.
    Oteri J; Bawa S; Christopher E; Nsubuga P; Dieng B; Braka F; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C60-C65. PubMed ID: 33451781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach.
    Campbell JD; Pasetti MF; Oot L; Adam Z; Tefera M; Beyane B; Mulholland N; Steinglass R; Krey R; Chen WH; Blackwelder WC; Levine MM
    Vaccine; 2021 Sep; 39(40):5802-5813. PubMed ID: 34465472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons learned in the implementation of supplementary immunization activity (SIA) field guidelines for injectable vaccines - Experiences from Tanzania.
    Mohamed N; Simba D; Mphuru A; Lyimo D; Kyesi F
    Vaccine; 2020 Nov; 38(49):7741-7746. PubMed ID: 33164797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polio Legacy in Action: Using the Polio Eradication Infrastructure for Measles Elimination in Nigeria-The National Stop Transmission of Polio Program.
    Michael CA; Waziri N; Gunnala R; Biya O; Kretsinger K; Wiesen E; Goodson JL; Esapa L; Gidado S; Uba B; Nguku P; Cochi S
    J Infect Dis; 2017 Jul; 216(suppl_1):S373-S379. PubMed ID: 28838182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting poor measles vaccination coverage in sub-Saharan Africa with a special focus on Nigeria: a narrative review.
    Majekodunmi OB; Oladele EA; Greenwood B
    Trans R Soc Trop Med Hyg; 2022 Aug; 116(8):686-693. PubMed ID: 35294971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
    Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
    BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First 5 years of measles elimination in southern Africa: 1996-2000.
    Biellik R; Madema S; Taole A; Kutsulukuta A; Allies E; Eggers R; Ngcobo N; Nxumalo M; Shearley A; Mabuzane E; Kufa E; Okwo-Bele JM
    Lancet; 2002 May; 359(9317):1564-8. PubMed ID: 12047966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a measles immunisation campaign on measles admissions to a Natal hospital.
    Abdool Karim SS; Abdool Karim Q; Chamane M
    S Afr Med J; 1991 Dec; 80(11-12):579-81. PubMed ID: 1745947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using geospatial models to map zero-dose children: factors associated with zero-dose vaccination status before and after a mass measles and rubella vaccination campaign in Southern province, Zambia.
    Arambepola R; Yang Y; Hutchinson K; Mwansa FD; Doherty JA; Bwalya F; Ndubani P; Musukwa G; Moss WJ; Wesolowski A; Mutembo S
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34969682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles vaccination coverage in high-incidence areas of the Western Cape, following the mass vaccination campaign.
    Bernhardt GL; Cameron NA; Willems B; Boulle A; Coetzee D
    S Afr Med J; 2013 Jan; 103(3):181-6. PubMed ID: 23472696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of targeted urban supplemental measles vaccination campaigns (1997-1999) to prevent measles epidemics in Mozambique (1998-2001).
    Cliff J; Simango A; Augusto O; Van Der Paal L; Biellik R
    J Infect Dis; 2003 May; 187 Suppl 1():S51-7. PubMed ID: 12721891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovations in communication technologies for measles supplemental immunization activities: lessons from Kenya measles vaccination campaign, November 2012.
    Mbabazi WB; Tabu CW; Chemirmir C; Kisia J; Ali N; Corkum MG; Bartley GL
    Health Policy Plan; 2015 Jun; 30(5):638-44. PubMed ID: 24920218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an immunisation campaign in Natal and KwaZulu on vaccinaton coverage rates, 1990-1991.
    Dyer JJ; Naidoo KN; Knight S; Mjekevu T; Munro G; Robinson A
    S Afr Med J; 1996 Feb; 86(2):158-61. PubMed ID: 8619143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cluster survey evaluation of a measles vaccination campaign in Jharkhand, India, 2012.
    Scobie HM; Ray A; Routray S; Bose A; Bahl S; Sosler S; Wannemuehler K; Kumar R; Haldar P; Anand A
    PLoS One; 2015; 10(5):e0127105. PubMed ID: 26010084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.